Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile
Nate O'Connell, PhD

@nateoconnellphd

PhD Biostatistician; Assistant Prof @WakeBDS @wakeforestmed & @WakeCancer; clinical trials, Bayesian stats, prediction models, applied stats; Views are my own

ID: 164796637

calendar_today09-07-2010 19:48:35

92 Tweet

182 Takipçi

387 Takip Edilen

Ashish K. Khanna, MD,MS,FCCP,FCCM,FASA (@khannaashishccm) 's Twitter Profile Photo

15k patients wireless wearable hemodynamic monitoring outside ICU Atrium Health Wake Forest Baptist q15 seconds MAP,SBP,HR with linked alarms. Hemodynamic disturbances common on hospital wards-majority are missed without continuous monitoring. ASA® APSF Society of Critical Care Anesthesiologists SCCM ASER

15k patients wireless wearable hemodynamic monitoring outside ICU <a href="/AtriumHealthWFB/">Atrium Health Wake Forest Baptist</a> q15 seconds MAP,SBP,HR with linked alarms. Hemodynamic disturbances common on hospital wards-majority are missed without continuous monitoring. <a href="/ASALifeline/">ASA®</a> <a href="/APSForg/">APSF</a> <a href="/SOCCA_CritCare/">Society of Critical Care Anesthesiologists</a> <a href="/SCCM/">SCCM</a> <a href="/ASER_hq/">ASER</a>
Ashish K. Khanna, MD,MS,FCCP,FCCM,FASA (@khannaashishccm) 's Twitter Profile Photo

Ken Tegtmeyer, MD, FCCM, FAAP 🇺🇸 🟧 Raw numbers suggest a relationship with clinical deterioration. Still working to finalize the results of clinicaltrials.gov/ct2/show/NCT04… Nate O'Connell, PhD Alarm fatigue needs a deeper understanding of the human element of response to monitoring alerts!

Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

Reviewing proofs for an accepted paper. In reference to the Bayesian model specified, the editorial office changed “prior distributions” to “previous distributions”. I had a good laugh 🤦🏻

Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

I’m excited to share our paper just published today by Journal of Clinical Oncology: “Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial” ascopubs.org/doi/10.1200/JC…

Dr. Iván R. González (@dr_ivanoncologo) 's Twitter Profile Photo

🔍 Enlightening E1912 Trial analysis! Discussing the relevance of reporting G1 &G2 AEs. 🔹G2 AEs increase the odds of treatment discontinuation by 59% (95% CrI, 1.32-1.95). 💊🔸Each G1 & G2 AE during a treatment cycle boosts odds of self-reported patient side-effect bother by 13%

🔍 Enlightening E1912 Trial analysis! Discussing the relevance of reporting G1 &amp;G2 AEs.
🔹G2 AEs increase the odds of treatment discontinuation by 59% (95% CrI, 1.32-1.95). 💊🔸Each G1 &amp; G2 AE during a treatment cycle boosts odds of self-reported patient side-effect bother by 13%
Stephen John Senn (@stephensenn) 's Twitter Profile Photo

Just because simple random sampling is what you came across in stat 101 does not mean that it applies to most let alone all of the data sets you will encounter.

Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

As a previous Thomas C. Chalmers scholarship recipient (2016), this is a great opportunity for graduate students to have the possibility to attend the SCT meeting. If you have graduate students working in trials, I'd highly encourage them to apply!

Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

A summary of our recently published paper in Journal of Clinical Oncology featured in ASCO Daily News: Low- and Moderate-Grade Adverse Events Increase Odds of Treatment Discontinuation in Hematologic Malignancies ascopubs.org/doi/10.1200/AD…

Kareem Carr, Statistics Person (@kareem_carr) 's Twitter Profile Photo

I honestly think this is one of the most powerful ideas humans have ever discovered and it’s weird to me that we don’t talk about it as much as F=ma or E=mc²

I honestly think this is one of the most powerful ideas humans have ever discovered and it’s weird to me that we don’t talk about it as much as F=ma or E=mc²
Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

Insightful commentary in this editorial on the collection of low-moderate AEs in response to our original paper in Journal of Clinical Oncology - Patient Experience, Adverse Event Reporting, and Clinical Trial Design | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

JAMA (@jama_current) 's Twitter Profile Photo

Acetaminophen use during pregnancy was not associated with children’s risk of autism, ADHD, or intellectual disability in sibling control analysis. ja.ma/3TUB3qy

Acetaminophen use during pregnancy was not associated with children’s risk of autism, ADHD, or intellectual disability in sibling control analysis. 

ja.ma/3TUB3qy
Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

Excited to share coverage by Oncology Times of our work on the importance of low-grade AEs and their impact on treatment discontinuation and patient side-effect burden from the ECOG-ACRIN Cancer Research Group trial E1912 published in Journal of Clinical Oncology! See here: journals.lww.com/oncology-times… Lynne I Wagner PhD

Nate O'Connell, PhD (@nateoconnellphd) 's Twitter Profile Photo

Excited to share our newly published paper “A comparison of random forest variable selection methods for regression modeling of continuous outcomes” with Jaime Lynn Speiser Garrett Bullock PT, DPT, DPhil and Byron Jaeger academic.oup.com/bib/article/26…